PLUR: Pluri Inc. Stock

by  •  • Comments Off on PLUR: Pluri Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 32.75
Enterprise Value ($M) 54.43
Book Value ($M) -2.92
Book Value / Share -0.42
Price / Book -11.23
NCAV ($M) -11.41
NCAV / Share -1.63
Price / NCAV -2.87

Profitability (mra)
Return on Invested Capital (ROIC) -0.75
Return on Assets (ROA) -0.48
Return on Equity (ROE) -3.00

Liquidity (mrq)
Quick Ratio 5.04
Current Ratio 5.04

Balance Sheet (mrq) ($M)
Current Assets 22.37
Assets 30.86
Liabilities 33.78
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.33
Operating Income -22.16
Net Income -20.89
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -18.02
Cash from Investing 10.58
Cash from Financing 8.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-12 13D Chutzpah Holdings Ltd
2024-02-13 13G/A Shayna LP 8.10

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT UNDE
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT UND
2024-09-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT T
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-11 3,812 6,029 63.23
2025-03-10 223 3,978 5.61
2025-03-07 1,226 9,831 12.47
2025-03-06 12,215 24,646 49.56

(click for more detail)

Similar Companies
PCSA – Processa Pharmaceuticals, Inc. PDSB – PDS Biotechnology Corporation
PHIO – Phio Pharmaceuticals Corp. PMCB – PharmaCyte Biotech, Inc.
PMN – ProMIS Neurosciences, Inc.


Financial data and stock pages provided by
Fintel.io